Please activate JavaScript!
Please install Adobe Flash Player, click here for download
ePaper created 2014-10-06, 13:17:01 | version 1.33.00
for the integrity of the data and accuracy of the data analysis. All authors meet the ICMJE criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published. Conflict of interest. Jan Leendert Pouwel Brouwer and Hugo Stoevelaar declare no conflict of interest and no financial or commercial relationships with relevant companies. Christoph Sucker has provided consultancy in medical advice to Alere on other projects not related to this analysis. Compliance with ethics guidelines. The analysis in this article is based on a retrospective examination of anonymous, aggregated patient data, and does not involve any new studies of human subjects performed by any of the authors. Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. REFERENCES 1. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369–429. 2. Friberg L, Bergfeldt L. Atrial fibrillation prevalence revisited. J Intern Med. 2013;274(5):461–8. 3. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–67. 4. Morgan CL, McEwan P, Tukiendorf A, Robinson PA, Clemens A, Plumb JM. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb Res. 2009;124(1):37–41. 5. Torn M, Cannegieter SC, Bollen WL, van der Meer FJ, van der Wall EE, Rosendaal FR. Optimal level of oral anticoagulant therapy for the prevention of arterial thrombosis in patients with mechanical heart valve prostheses, atrial fibrillation, or myocardial infarction: a prospective study of 4202 patients. Arch Intern Med. 2009;169(13):1203–9. 6. Veeger NJ, Piersma-Wichers M, Tijssen JG, Hillege HL, van der Meer J. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism. Br J Haematol. 2005;128(4):513–9. 7. Heneghan C, Ward A, Perera R, et al. Self- monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet. 2012;379(9813):322–34. 8. DeSantis G, Hogan-Schlientz J, Liska G, et al. STABLE results: warfarin home monitoring achieves excellent INR control. Am J Manag Care. 2014;20(3):202–9. 9. Cumberworth A, Mabvuure NT, Hallam MJ, Hindocha S. Is home monitoring of international normalised ratio safer than clinic-based monitoring? Interact CardioVasc Thorac Surg. 2013;16(2):198–201. 10. Garcia-Alamino JM, Ward AM, Alonso-Coello P. Self-monitoring and self-management of oral anticoagulation. Cochrane Database Syst Rev. 2010;4:CD003839. 11. Bloomfield HE, Krause A, Greer N, et al. Meta- analysis: effect of patient self-testing and self- management of long-term anticoagulation on major clinical outcomes. Ann Intern Med. 2011;154:472–82. 12. Heneghan C, Alonso-Coello P, Garcia-Alamino JM, Perera R, Meats E, Glasziou P. Self-monitoring of oral anticoagulation: a systematic review and meta- analysis. Lancet. 2006;367(9508):S404–11. 13. Holbrook A, Schulman S, Witt DM, et al. Evidence- based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e152S–84S. Adv Ther